Progression of Hearing Loss in Neurofibromatosis Type 2 According to Genetic Severity
dc.contributor.author | Hanemann, Clemens Oliver | |
dc.contributor.author | Emmanouil, B | |
dc.contributor.author | Houston, R | |
dc.contributor.author | May, A | |
dc.contributor.author | Ramsden, JD | |
dc.contributor.author | Halliday, D | |
dc.contributor.author | Parry, A | |
dc.contributor.author | Mackeith, S | |
dc.date.accessioned | 2018-11-27T14:13:37Z | |
dc.date.issued | 2019-04 | |
dc.identifier.issn | 0023-852X | |
dc.identifier.issn | 1531-4995 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/12913 | |
dc.description.abstract |
<jats:sec><jats:title>Objectives/Hypothesis</jats:title><jats:p>This study set out to describe the progression of hearing loss in patients with neurofibromatosis type 2 (NF2), treated in a quaternary multidisciplinary clinic. It also aimed to compare hearing loss across patients grouped according to a known genetic severity score to explore its utility for prognostication.</jats:p></jats:sec><jats:sec><jats:title>Study Design</jats:title><jats:p>Retrospective cohort study.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We conducted a study of 147 patients with confirmed NF2 diagnosis for a mean observational period of 10 years. Pure‐tone average (PTA), optimum discriminations scores (ODS), and genotype data were collected. Patients were classified according to hearing class (American Academy of Otolaryngology), their candidacy for auditory implantation (UK National NF2 consensus) and grouped by genetic severity as: 1 = tissue mosaic, 2A = mild classic, 2B = moderate classic, and 3 = severe. Survival analysis investigated the effect of genetic severity on the age of loss of serviceable hearing.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Genetic severity was a significant predictor of hearing outcomes such as ODS, hearing classification, and maximum annual PTA deterioration. Although the overall median age of loss of serviceable hearing was 78 years, there was significant variation according to the genetic severity; the median for severe patients was 32 years compared to a median of 80 for tissue mosaic patients.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>This is the first description of long‐term hearing outcomes in a clinical setting across a large heterogeneous cohort of patients with NF2. The results highlight the potential importance and benefit of considering the genetic severity score of patients when undertaking treatment decisions, as well as planning future natural history studies.</jats:p></jats:sec><jats:sec><jats:title>Level of Evidence</jats:title><jats:p>2c <jats:italic>Laryngoscope</jats:italic>, 129:974–980, 2019</jats:p></jats:sec> | |
dc.format.extent | 974-980 | |
dc.format.medium | Print-Electronic | |
dc.language | en | |
dc.language.iso | en | |
dc.publisher | Wiley | |
dc.subject | Neurofibromatosis 2 | |
dc.subject | genetic severity | |
dc.subject | natural history | |
dc.subject | hearing loss | |
dc.subject | acoustic neuroma | |
dc.subject | vestibular schwannoma | |
dc.title | Progression of Hearing Loss in Neurofibromatosis Type 2 According to Genetic Severity | |
dc.type | journal-article | |
dc.type | Journal Article | |
plymouth.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000462650400046&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008 | |
plymouth.issue | 4 | |
plymouth.volume | 129 | |
plymouth.publication-status | Published | |
plymouth.journal | The Laryngoscope | |
dc.identifier.doi | 10.1002/lary.27586 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/Peninsula Medical School | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
plymouth.organisational-group | /Plymouth/Users by role/Researchers in ResearchFish submission | |
dc.publisher.place | United States | |
dcterms.dateAccepted | 2018-08-29 | |
dc.rights.embargodate | 2019-11-19 | |
dc.identifier.eissn | 1531-4995 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.versionofrecord | 10.1002/lary.27586 | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2019-04 | |
rioxxterms.type | Journal Article/Review |